TITLE

Surfactant replacement therapy in ARDS: white knight or noise in the system?

AUTHOR(S)
Nicholas, Terence E.; Doyle, Ian R.; Bersten, Andrew D.
PUB. DATE
February 1997
SOURCE
Thorax;Feb1997, Vol. 52 Issue 2, p195
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66296686

 

Related Articles

  • Is Surfactant a Promising Additive Drug in ALI / ARDS-Patients? Schultz, Marcus J.; Kesecioglu, Jozef // Current Drug Targets;Jul2004, Vol. 5 Issue 5, p445 

    The rationale for surfactant replacement therapy in patients with acute respiratory distress syndrome (ARDS) is to restore the normal composition of the surfactant system, as well as to overcome ongoing inactivation of present surfactant. Indeed, surfactant replacement therapy can normalize the...

  • SURFACTANT REPLACEMENT THERAPY INCREASES LIFE-SPAN OF PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME. Potapov, A. L.; Novikov, N. Yu.; Tumanskiy, V. A.; Babanin, A. A. // Global Built Environment Review;Feb2013, Vol. 8 Issue 2, p3 

    The aim of the study is the evaluation of the influence of surfactant replacement therapy on the life-span of patients with acute respiratory distress syndrome (ARDS) in fatal cases. It has been determined, that in patients, were died from ARDS, exogenous surfactant therapy increases life-span...

  • Pulmonary surfactant: functions, abnormalities and therapeutic options. Frerking, Ilka; Günther, Andreas; Seeger, Werner; Pison, Ulrich // Intensive Care Medicine;Nov2001, Vol. 27 Issue 11, p1699 

    The first successful clinical pilot studies of surfactant replacement were published about 20 years ago as a logical extension of experimental studies showing beneficial effects in pre-term animals. The efficacy of this therapy for immature new-borns has been confirmed in various controlled...

  • Surfactant Replacement Therapy in Pediatric Acute Lung Injury/Acute Respiratory Distress Syndrome. Cox, Timothy J.; Bhatia, Rahul; Hertzog, James H. // Current Respiratory Medicine Reviews;2009, Vol. 5 Issue 3, p160 

    Surfactant dysfunction has been demonstrated in clinical and experimental studies of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Inflammatory mediators, alveolar exudation, capillary endotheliopathy, and various other mechanisms have been indicted as the cause of...

  • Exogenous Surfactant Replacement in ARDS – One Day, Someday, or Never? Baudouin, Simon V. // New England Journal of Medicine;8/26/2004, Vol. 351 Issue 9, p853 

    The article presents an editorial regarding the treatment with exogenous surfactant for the acute respiratory distress syndrome (ARDS). An article by Spragg and coworkers in this issue of the journal is referenced which reported on a clinical study in which patients who received the surfactant...

  • Therapy for bronchopulmonary dysplasia in premature infants focuses on reducing the effects of oxygen toxicity and mechanical ventilation. Adis International Limited // Drugs & Therapy Perspectives;Jul2005, Vol. 21 Issue 7, p11 

    Discusses the management of bronchopulmonary dysplasia (BPD) in premature infants. Benefits of surfactant replacement therapy in intubated infants; Side effects of systemic glucocorticoids; Usefulness of oxygen therapy.

  • The Future of Exogenous Surfactant Therapy. Willson, Douglas F.; Notter, Robert H. // Respiratory Care;Sep2011, Vol. 56 Issue 9, p1369 

    Since the identification of surfactant deficiency as the putative cause of the infant respiratory distress syndrome (RDS) by Avery and Mead in 1959, our understanding of the role of pulmonary surfactant in respiratory physiology and the pathophysiology of acute lung injury (ALI) has advanced...

  • Pulmonary surfactant: a front line of lung host defense. Wright, Joe Rae // Journal of Clinical Investigation;5/15/2003, Vol. 111 Issue 10, p1453 

    Investigates the functions of lung innate immune system, pulmonary surfactant. Description of pulmonary surfactant; Antibacterial functions of the surfactant; Surfactant therapy for infectious and inflammatory lung diseases.

  • Pharmacotherapy for Prevention and Treatment of Acute Respiratory Distress Syndrome: Current and Experimental Approaches. Bosma, Karen J.; Taneja, Ravi; Lewis, James F. // Drugs;2010, Vol. 70 Issue 10, p1255 

    The acute respiratory distress syndrome (ARDS) arises from direct and indirect injury to the lungs and results in a life-threatening form of respiratory failure in a heterogeneous, critically ill patient population. Critical care technologies used to support patients with ARDS, including...

  • AKUT RESPÄ°RATUAR DÄ°STRES SENDROMUNDA GÃœNCEL MEKANÄ°K VENTÄ°LASYON UYGULAMALARI. Kaya Uğur, Berna; Ganidağlı, Süleyman // Bulletin of Thoracic Surgery / Toraks Cerrahisi Bülteni;Sep2014, Vol. 5 Issue 3, p180 

    ARDS is an inflammatory process that can be life-threatening respiratory failure. ARDS can be a directly derived lung injury from infection or aspiration of gastric contents or an indirect injury that can be derived from an extrapulmonary process. Although more than 60 reasons have been defined,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics